Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-2 Post-Transplant in Non-Hodgkin's Lymphoma
NCT00002649Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- May 1995
- Primary completion
- Nov 2006
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-Hodgkin lymphoma (NHL) comparing Aldesleukin with Observation (2 arms). Primary endpoints: Overall Survival at 13 years, Disease-Free Survival at 13 years and 1 more. Started May 1995; status: completed.
02
Drugs
aldesleukin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00002649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002649.